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Recent efforts in malaria control have resulted in great gains in reducing the burden of Plas-
modium falciparum, but P. vivax has been more refractory. Its ability to form dormant liver
stages confounds control and elimination efforts. To compare the efficacy and safety of pri-
maquine regimens for radical cure, we undertook a randomized controlled trial in Ethiopia.
Methods and findings
Patients with normal glucose-6-phosphate dehydrogenase status with symptomatic P. vivax
mono-infection were enrolled and randomly assigned to receive either chloroquine (CQ) or
artemether-lumefantrine (AL), alone or in combination with 14 d of semi-supervised prima-
quine (PQ) (3.5 mg/kg total). A total of 398 patients (n = 104 in the CQ arm, n = 100 in the AL
arm, n = 102 in the CQ+PQ arm, and n = 92 in the AL+PQ arm) were followed for 1 y, and
recurrent episodes were treated with the same treatment allocated at enrolment. The pri-
mary endpoints were the risk of P. vivax recurrence at day 28 and at day 42.
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The risk of recurrent P. vivax infection at day 28 was 4.0% (95% CI 1.5%–10.4%) after
CQ treatment and 0% (95% CI 0%–4.0%) after CQ+PQ. The corresponding risks were
12.0% (95% CI 6.8%–20.6%) following AL alone and 2.3% (95% CI 0.6%–9.0%) following
AL+PQ. On day 42, the risk was 18.7% (95% CI 12.2%–28.0%) after CQ, 1.2% (95% CI
0.2%–8.0%) after CQ+PQ, 29.9% (95% CI 21.6%–40.5%) after AL, and 5.9% (95% CI
2.4%–13.5%) after AL+PQ (overall p < 0.001). In those not prescribed PQ, the risk of recur-
rence by day 42 appeared greater following AL treatment than CQ treatment (HR = 1.8
[95% CI 1.0–3.2]; p = 0.059). At the end of follow-up, the incidence rate of P. vivax was 2.2
episodes/person-year for patients treated with CQ compared to 0.4 for patients treated with
CQ+PQ (rate ratio: 5.1 [95% CI 2.9–9.1]; p < 0.001) and 2.3 episodes/person-year for AL
compared to 0.5 for AL+PQ (rate ratio: 6.4 [95% CI 3.6–11.3]; p < 0.001). There was no dif-
ference in the occurrence of adverse events between treatment arms.
The main limitations of the study were the early termination of the trial and the omission
of haemoglobin measurement after day 42, resulting in an inability to estimate the cumula-
tive risk of anaemia.
Conclusions
Despite evidence of CQ-resistant P. vivax, the risk of recurrence in this study was greater
following treatment with AL unless it was combined with a supervised course of PQ. PQ
combined with either CQ or AL was well tolerated and reduced recurrence of vivax malaria




Why was this study done?
• In areas where Plasmodium vivax is endemic, recurrent parasitaemia arises from chloro-
quine (CQ) resistance and the reactivation of dormant hypnozoites. Recurrent parasi-
taemia is associated with significant morbidity and mortality. Providing safe and
effective radical cure of blood and liver stages of the parasite is critical for the control
and elimination of P. vivax malaria.
• Two systematic reviews of P. vivax clinical trials highlighted a declining efficacy for CQ
in many P. vivax endemic areas and marked heterogeneity in study design for determin-
ing primaquine (PQ) efficacy. The conclusions of these reviews were that clinical trials
to determine the efficacy of radical cure should follow up patients for a prolonged
period to capture late relapses and should quantify the incidence rate of multiple recur-
rences, not just the time to the first recurrence.
• The rise in CQ-resistant P. vivax provides a good rationale for artemisinin combination
therapy for P. vivax malaria; however, the efficacy of artemisinin combination therapies
in combination with PQ radical cure is poorly documented.
Radical cure of P. vivax malaria in Ethiopia
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What did the researchers do and find?
• We randomized patients to four treatment arms: one group received CQ only (the cur-
rent recommended treatment for P. vivax malaria in Ethiopia), the second group
received CQ plus PQ, the third group received artemether-lumefantrine (AL) alone, and
the fourth group received AL plus PQ. All patients were followed up for a year and were
treated with the same treatment for every P. vivax malaria episode.
• We quantified the risk of P. vivax infections at day 28 after treatment and also over 12
months. The risk of recurrence by day 28 and 42 was greater following AL than CQ. The
addition of PQ to either CQ or AL reduced the risk of recurrence 3-fold by day 42, and
2- to 3-fold over one year.
• Patients treated with PQ had on average only 0.5 P. vivax malaria episodes per year,
whereas patients not treated with PQ had on average two episodes per year. The efficacy
of PQ treatment for recurrences, which was unsupervised, was 3- to 4-fold lower than
that of the initial treatment, which was semi-supervised.
What do these findings mean?
• In Ethiopia there is evidence of CQ resistance; nevertheless, in this study CQ monother-
apy had greater efficacy than AL therapy at day 42.
• The addition of PQ radical cure to either CQ or AL provided major benefits in reducing
subsequent recurrent infection.
• PQ radical cure should be included in the treatment schedule in Ethiopia and other
areas with high relapse risk to reduce relapsing infection and transmission, but further
work is needed to improve adherence to the current 14-day regimen to ensure maxi-
mum public health impact.
Introduction
Almost 3 billion people live at risk of Plasmodium vivax infection [1,2], with over 100 million
clinical malaria cases estimated to occur each year [3]. The greatest burden of P. vivax malaria
is in the Asia-Pacific region and South America, whereas on the African continent, P. vivax
infection is limited mostly to the Horn of Africa. Recent intensification of malaria control
efforts has reduced the global burden of P. falciparum malaria, but P. vivax has been more
refractory. Vivax malaria is more difficult to cure than falciparum malaria, due to its ability to
form dormant liver stages (hypnozoites) that reactivate periodically, causing relapsing infec-
tions and onward transmission. Chloroquine (CQ) remains the mainstay of treatment for
vivax malaria in most endemic countries, but drug resistance has emerged in South-East Asia
and is spreading [4]. Relapsing and increasingly frequent recrudescent infections cause
repeated symptomatic illnesses, worsening the risk of anaemia and severe and fatal disease
[5,6].
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Although P. vivax is rare on the African continent outside the Horn of Africa, in Ethiopia it
is responsible for approximately 40% of all clinical malaria [7–9]. National treatment guidelines
recommend CQ as first-line treatment for uncomplicated P. vivax malaria. Artemether-lume-
fantrine (AL) is used widely for mixed-species infections of P. falciparum and P. vivax, and for
cases of clinical malaria where diagnostics to determine the Plasmodium species are unavailable.
Both CQ and AL have schizonticidal efficacy but lack activity against the liver stages. Prima-
quine (PQ), an 8-aminoquinoline, is the only currently available hypnozoiticide, but can cause
severe haemolysis in glucose-6-phosphate-dehydrogenase (G6PD)–deficient patients; for this
reason, programmes are often reluctant to recommend PQ, and healthcare providers are hesi-
tant to prescribe it. Ethiopia has embarked on an ambitious malaria control programme, sup-
porting the country’s Health Sector Development Plan as well as the national child survival
strategy. The control and elimination of malaria will require deployment of a safe and effective
radical cure of P. vivax. At the time this study was conducted, PQ radical cure was not part of
the national antimalarial guidelines for patients living in malaria endemic areas of the country.
To compare suitable treatment strategies, we undertook a randomized controlled trial of the
efficacy of PQ in combination with CQ or AL at two sites in Oromia Region, Ethiopia.
Methods
Ethics
Ethical approval for the study was granted by the National Research Ethics Review Committee
in Ethiopia (3.10/801/05), the Human Research Ethics Committee of the Northern Territory
Department of Health and Menzies School of Health Research in Australia (HREC 2013–
1938), the US Centers for Disease Control and Prevention Institutional Review Board B
(6338.0), and the Columbia University Institutional Review Board (AAAK4706).
Study design and participants
The study was designed as an open-label randomized controlled trial with four arms, con-
ducted at the Bishoftu Malaria Control Center and the Batu Health Center in Oromia Region,
in central Ethiopia (S1 Text). Bishoftu is approximately 50 km south of Addis Ababa, and Batu
a further 115 km south. The main transmission season is between September and November,
and healthcare facility data confirmed P. vivax to be the dominant malaria species. Anopheles
arabiensis is the primary malaria vector, and the prevalence of malaria in Oromia Region was
0.4% during the 2011 national malaria indicator survey [10]. Patients seeking care with sus-
pected malaria were screened for the following inclusion criteria: slide-confirmed mono-infec-
tion with P. vivax, age> 1 y, weight 5.0 kg, living within 20 km of the enrolling health
facility, and axillary temperature 37.5˚C or history of fever during the previous 48 h. Patients
were excluded if they were pregnant or breastfeeding, had danger signs or severe manifesta-
tions of malaria, signs of severe malnutrition, slide-confirmed infection with any other Plasmo-
dium species besides P. vivax, acute anaemia (haemoglobin [Hb]< 80 g/l) or history of
haemolysis, known hypersensitivity to any of the study drugs, other significant comorbidities,
or regular medication that could interfere with their antimalarial treatment. All participants or
their guardian/caregiver agreed to finger prick sampling and provided written informed
consent.
Randomization
Patients were randomized in a two-stage process: (i) at enrolment, randomization to either
CQ or AL schizonticidal treatment and (ii) on day 2, after G6PD testing, randomization into
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the PQ or no-PQ arms. Patients with severe or intermediate G6PD deficiency were excluded
from the second randomization to PQ. The randomization sequence was computer-generated
by one of the investigators and kept in sealed opaque envelopes. Randomization was done in
blocks of eight for each site separately. Clinicians enrolled the patients, and nurses assigned
the patients sequentially according to the sealed envelopes.
Study procedures
Treatment. CQ (Micro Labs Limited, Tamil Nadu, India) was prescribed according to
national guidelines at 25 mg base/kg over 3 d (10 mg base/kg on days 0 and 1, and 5 mg base/
kg on day 2). AL (20 mg of artemether and 120 mg of lumefantrine; Novartis Pharmaceuticals
Corporation, New York, NY, US) was administered twice daily for 3 d according to the manu-
facturer’s recommendations. The CQ and AL tablets used in the study were certified and pro-
vided by the World Health Organization Global Malaria Programme. Initial schizonticidal
treatment with CQ was fully supervised, whereas for AL only the morning dose was super-
vised, and the second dose taken unsupervised at home. PQ (Sanofi-Aventis, Bridgewater, NJ,
US) was prescribed at 0.25 mg/kg daily dose over 14 d starting on day 2, and administration
was semi-supervised during the initial episode, with directly observed treatment (DOT) on
days 2, 3, 7, 10, and 14; doses in between were self-administered. For all subsequent episodes
of malaria, schizonticidal as well as PQ treatment was unsupervised.
All patients were observed for 60 min after treatment for adverse reactions or vomiting
when administered under supervision. Patients vomiting their medication within the first 30
min received a repeat full dose; patients vomiting within 30–60 min received half the original
dose. Patients failing treatment in any arm within 14 d were treated with quinine 10 mg/kg
every 8 h for 7 d as per the national guideline.
Clinical procedures. During screening, a G6PD test was carried out on all patients, and a
pregnancy test on all adult females. At enrolment, patients had a medical examination, a ques-
tionnaire was completed, and a capillary blood sample was collected for blood film examina-
tion and Hb measurement. Three 50-μl capillary blood spots were stored on filter papers
(Whatman 903 and Whatman 3; GE Healthcare Biosciences, Westborough, MA, US). In con-
senting patients, venous blood samples were collected at enrolment and, if malaria recurred,
on the day of recurrence.
Patients were asked to return for routine assessment daily for the first 3 d, then weekly until
day 42, and thereafter monthly for an additional 10 mo. Patients were also asked to return to
the clinic if they had signs or symptoms consistent with malaria, and those with recurrent clin-
ical P. vivax malaria occurring more than 14 d following treatment received the same treat-
ment as that allocated at enrolment, with subsequent follow-up according to the initial
schedule.
A follow-up medical exam and blood film examination was undertaken on days 1, 2, 3, 7,
14, 21, 28, 35, and 42, and monthly thereafter for 10 mo. Adverse drug reactions and concomi-
tant medications were recorded at every visit, with repeat Hb concentration measured on days
3, 7, 14, 21, 28, 35, and 42.
Laboratory procedures. G6PD status was determined by NADPH fluorescent spot test
(Trinity Biotech, Bray, Ireland). Hb concentration was measured using a HemoCue Hb 301
instrument (HemoCue, Angelholm, Sweden). Blood film examination was undertaken by two
certified microscopists, and all slides read independently. Blood smears with discordant results
(differences between the two microscopists in species diagnosis, in parasite density of>50%,
or in regard to the positivity of the smear) were re-examined by a third, independent micros-
copist, and parasite density was calculated by averaging the two closest counts.
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PCR-based species confirmation was undertaken on all clinical samples on day 0 and the
day of any recurrence until day 42 using a genus/P. falciparum duplex PET-PCR assay [11]
and an in-house P. vivax PET-PCR assay. Parasite genotyping was undertaken using seven
microsatellite markers as described previously [12,13] (S2 Text).
When recurrence of P. vivax occurred before day 28, whole blood concentrations of CQ
and its metabolite desethylchloroquine (DCQ) were measured from dried blood spots col-
lected on the day of recurrence using an HPLC method [14]. The limit of detection for both
CQ and DCQ was 5 ng/ml. Levels< 5 ng/ml were designated as below detection.
Outcome
The primary endpoint was the cumulative risk of P. vivax recurrence at day 28 and day 42
following treatment of the first episode of malaria, comparing AL with AL+PQ and CQ with
CQ+PQ. A secondary endpoint was the cumulative risk at day 28 for AL compared with CQ
and for AL+PQ compared with CQ+PQ. Other secondary endpoints included parasite and
fever clearance, and cumulative risk and incidence rate of recurrences at the end of the
study. Safety endpoints were the proportion of patients with adverse events (AEs) and seri-
ous AEs, the fractional change in Hb, the proportion of patients with a >25% drop in Hb
between baseline and day 7, and the proportion of patients with anaemia (Hb < 100 g/l) on
days 3 and 7. Haematological recovery at day 28 was defined as an Hb value on day 28 above
baseline.
Statistical analysis
The sample size was based on a power calculation assuming an efficacy of 68% at day 42 after
CQ monotherapy and that the addition of PQ would increase this to 87%. A total of 97 in each
group would achieve 90% power to detect this difference between groups. Adjusting the alpha
level to 0.025 for multiple comparisons and estimating 15% loss to follow-up increased the
proposed sample size to 120 per treatment arm.
Data were double-entered into a Microsoft Access database, and analyses conducted using
STATA 14 (StataCorp, College Station, TX, US), according to an a priori statistical analysis
plan (S3 Text). In view of the potential interaction between PQ and CQ [15] and between PQ
and AL [16], comparisons between each of the arms were undertaken separately, rather than
using a 2 × 2 factorial design approach, which assumes no interaction between the interven-
tions. The cumulative risks were calculated by survival analyses (Kaplan—Meier) at day 28,
day 42, and the end of the follow-up, and treatment groups compared using a Cox regression
model. The proportional hazards assumption was assessed by visually comparing the log
(cumulative hazard) by time of follow-up curves for each co-variable category and subse-
quently by fitting and comparing models with and without time of follow-up interaction
terms. Genotyping results were used to calculate adjusted cumulative risk of recurrence by
days 28 and 42 by censoring for heterologous infections, which may represent reinfection or
relapse; for this analysis, only PCR-confirmed P. vivax infections at enrolment were included
(S2 Text) [17]. The risks of recurrence after primary and secondary treatments were compared
at 6 mo to ensure sufficient patient follow-up time. Incidence rates were calculated from
microscopy results by dividing the number of P. vivax episodes by the number of person-years
of observation. Incidence rate ratios between treatment arms were derived from a negative
binomial regression model. The primary analysis was by intention to treat (ITT), and in the
secondary analysis a modified ITT approach was used, in which patients receiving incorrect
treatment or in whom no treatment information was available were censored on the day of the
recurrence. Patients with intermediate or deficient G6PD status were not included in the
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second stage of randomization; they were included only in descriptive results and were
excluded from any relevant comparisons between arms.
Results
Baseline characteristics
The study was conducted between 8 November 2012 and 31 December 2014, during which a
total of 1,177 patients were screened, and 398 (33.8%) enrolled in the study (Fig 1). In view of
logistical constraints and the lack of further patients with malaria, the study was terminated at
the end of the malaria season in 2014, after 82.9% (398/480) of the target sample size had been
recruited.
The majority of patients (77.1%, 307/398) were enrolled at the Bishoftu Malaria Control
Center. There were no important differences in baseline characteristics between the four treat-
ment arms (Table 1) or in the proportion of patients lost to follow-up by day 42. G6PD defi-
ciency was measured for 393 (98.7%) patients; missing values are mainly due to loss to follow-
up before day 2. Nine (2.3%, 9/393) patients had intermediate G6PD results; they were ran-
domized on day 0 for schizonticidal treatment, but did not receive PQ treatment (Table 1). In
total, 98.2% (391/398) of patients completed a full course of schizonticidal treatment, of whom
Fig 1. CONSORT flowchart of patient allocation for the day 42 outcome. AL, artemether-lumefantrine; AL+PQ, artemether-lumefantrine
+ primaquine; CQ, chloroquine; CQ+PQ, chloroquine + primaquine; G6PD, glucose-6-phosphate dehydrogenase; Lost, lost to follow-up.
https://doi.org/10.1371/journal.pmed.1002299.g001
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six (1.5%) vomited their dose within 1 h of administration (four in the CQ arm and two in the
AL arm). One patient vomited doses of AL on day 1 and 2.
Day 28 and 42 outcomes
There were 17 recurrent P. vivax infections documented within 28 d of follow-up, and a fur-
ther 34 between day 28 and 42 (27 in the AL arm, 18 in the CQ arm, five in the AL+PQ arm,
and one in the CQ+PQ arm) (Table 2). An additional five patients presented with a P. falcipa-
rum infection before day 28, and one more between day 28 and 42. Patients in treatment arms
that included PQ had significantly fewer recurrent malaria episodes than patients on schizonti-
cidal therapy alone. By day 28, the cumulative risk for P. vivax recurrence was 4.0% (95% CI
1.5%–10.4%) for patients treated with CQ alone compared to 0% (95% CI 0%–4.0%) for those
treated with CQ+PQ (p< 0.001). The corresponding risks were 12.0% (95% CI 6.8%–20.6%)
following AL alone and 2.3% (95% CI 0.6%–9.0%) following AL+PQ (hazard ratio [HR] = 5.1
[95% CI 1.1–23.5], p = 0.034) (Fig 2; Tables 2 and 3).
By day 42, the risk of recurrence had risen to 18.7% (95% CI 12.2%–28.0%) in the CQ arm
and 1.2% (95% CI 0.2%–8.0%) in the CQ+PQ arm (HR = 18.5 [95% CI 2.5–138.5], p = 0.005).






primaquine (n = 102)
Artemether-lumefantrine plus
primaquine (n = 92)
Health centre, n (percent)
Bishoftu 79 (76.0%) 73 (73.0%) 79 (77.5%) 76 (82.6%)
Batu 25 (24.0%) 27 (27.0%) 23 (22.5%) 16 (17.4%)
Male, n (percent) 64 (61.5%) 70 (70.0%) 68 (66.7%) 51 (55.4%)
Age (years), median (IQR) 18 (IQR 10.5–19.0) 18 (IQR 10.0–26.0) 17 (IQR 9.0–25.0) 18 (IQR 9.0–27.0)
Age, n (percent)
5 y 7 (6.7%) 12 (12.0%) 10 (9.8%) 8 (8.7%)
5–15 y 31 (29.8%) 31 (31.0%) 37 (36.3%) 28 (30.4%)
>15 y 66 (63.5%) 57 (57.0%) 55 (53.9%) 56 (60.9%)
Weight (kg), median (IQR) 50.0 (29.0–56.0) 48.0 (24.5–56.5) 46.0 (22.0–54.0) 45.5 (22.0–57.0)
Temperature (˚C), median (IQR) 36.8 (36.1–38.4) 37.3 (36.4–39.0) 37.3 (36.2–38.8) 37.0 (36.4–38.2)
Fever, n (percent) 37 (35.6%) 46 (46.0%) 43 (42.1%) 50 (54.3%)
History of fever, n (percent) 100 (98.0%) 98 (99.0%) 100 (99.0%) 90 (97.8%)





6,691 (5,464.7–8,193.0) 5,598 (4,492.6–6,975.4) 5,132 (4,036.8–6,523.6)
Gametocyte carriage, n (percent) 42 (40.4%) 47 (47.0%) 39 (38.2%) 43 (46.7%)
G6PD status, n (percent)
Normal 100 (97.1%) 90 (93.8%) 102 (100.0%) 92 (100.0%)
Intermediate 3 (2.9%) 6 (6.3%) 0 0
Deficient 0 0 0 0
Bednet use and insecticide use, n
(percent)
Household ownership of a bednet 33 (34.7%) 42 (42.0%) 36 (35.3%) 37 (40.7%)
Patient slept under bednet on the
night before enrolment
14 (13.5%) 17 (17.0%) 22 (21.6%) 22 (23.9%)
House was sprayed with insecticides 23 (22.1%) 22 (22.0%) 19 (18.6%) 18 (19.6%)
IQR, interquartile range; SD, standard deviation.
https://doi.org/10.1371/journal.pmed.1002299.t001
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The corresponding risk for patients in the AL arm was 29.9% (95% CI 21.6%–40.5%) com-
pared to 5.9% (95% CI 2.4%–13.5%) in the AL+PQ arm (HR = 5.9 [95% CI 2.3–15.3], p<
0.001) (Fig 2; Tables 2 and 3). In those not prescribed PQ, the risk of recurrence by day 42 was
greater following AL than CQ, although this difference was of borderline significance
(HR = 1.8 [95% CI 1.0–3.2], p = 0.059) (Table 3).
Genotyping was feasible in 90.9% (362/398) of parasite isolates on day 0 and in 90.2% (46/
51) of paired isolates from patients with recurrence prior to day 42. In total, 47.8% (22/46) of
the paired P. vivax isolates that could be assessed were homologous (S2 Text).
Blood chloroquine concentrations on the day of recurrence could be measured in two of
the four patients with recurrent infection before day 28 in the CQ arm, both of whom had CQ
blood concentrations greater than 100 nM.
Parasite and fever clearance
By day 1, 60.2% (124/206) of those treated with CQ were still parasitaemic compared to 31.8%
(61/192) of those treated with AL regimens (odds ratio = 3.3 [95% CI 2.2–5.0], p< 0.001). By
day 2, the prevalence of parasitaemia was 6.8% in the CQ arms and 2.6% in the AL arms. By
day 3, only two patients in the CQ arms remained parasitaemic (Table 4).
Table 2. Treatment failure and risk and incidence of recurrent parasitaemia.
Time point Outcome measure CQ (n = 104) CQ+PQ (n = 102) AL (n = 100) AL+PQ (n = 92)
Day 28 Lost to follow-up 6 8 8 6
Early treatment failure 1 0 0 0
Late treatment failure 3 0 11 2
P. falciparum parasitaemia 2 3 0 0
Adequate clinical and parasitological response 92 91 81 84
Cumulative risk of P. vivaxa 4.0 (1.5–10.4) 0 (0–4.0) 12.0 (6.8–20.6) 2.3 (0.6–9.0)
Day 42 Lost to follow-up 7 12 11 10
Early treatment failure 1 0 0 0
Late treatment failure 17 1 27 5
P. falciparum parasitaemia 2 4 0 0
Adequate clinical and parasitological response 77 85 62 77
Cumulative risk of P. vivaxa 18.7 (12.2–28.0) 1.2 (0.2–8.0) 29.9 (21.6–40.5) 5.9 (2.4–13.5)
End of follow-up Lost to follow-up 15 39 22 28
Early treatment failure 1 0 0 0
Late treatment failure 56 14 62 17
P. falciparum parasitaemia 3 5 0 0
Adequate clinical and parasitological response 29 44 16 47
Cumulative risk of P. vivaxa 61.7 (51.9–71.7) 20.5 (13–31.5) 72.4 (62.5–81.6) 22.0 (14.2–33.1)
Incidence of P. vivax recurrenceb 2.2 (1.8–2.6) 0.4 (0.3–0.6) 2.3 (1.9–2.7) 0.5 (0.3–0.7)
Adjusted incidence of P. vivax recurrencec 2.3 (1.9–2.7) — 2.2 (1.8–2.6) —
Incidence of any Plasmodium recurrenceb 2.2 (1.9–2.7) 0.5 (0.4–0.7) 2.3 (1.9–2.7) 0.5 (0.4–0.7)
Adjusted incidence of any Plasmodium recurrencec 2.3 (1.9–2.8) — 2.2 (1.9–2.7) —
aCumulative risk derived from survival analysis, percent (95% CI).
bEpisodes per person-year of observation (95% CI); calculated from the duration of follow-up from first to last visit. Patients receiving antimalarial treatment
were assumed to have a period of 28 d of post-treatment prophylaxis after CQ treatment and 14 d of post-treatment prophylaxis after AL treatment, and this
period was subtracted from their total period of observation. This analysis included patients not randomized to PQ or no PQ.
cExcluding patients not randomized to PQ or no PQ.
AL, artemether-lumefantrine; AL+PQ, artemether-lumefantrine + primaquine; CQ, chloroquine; CQ+PQ, chloroquine + primaquine.
https://doi.org/10.1371/journal.pmed.1002299.t002
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Of the 166 patients with documented fever at enrolment, 96.4% (159/165) were afebrile
within 24 h, with 98.8% (84/85) in the AL arms compared to 93.8% (75/80) in the CQ arms
(p = 0.109) (Table 4).
Antirelapse efficacy
After 1 y of follow-up, 150 patients had experienced at least one recurrent episode of P. vivax
determined by microscopy (57 after CQ, 62 after AL, 14 after CQ+PQ, and 17 after AL+PQ),
and a further eight had had P. falciparum infections (three following CQ and five after CQ
+PQ) (Table 2). The risk of any recurrence of P. vivax was 61.7% (95% CI 51.9%–71.7%) fol-
lowing CQ alone compared to 72.4% (95% CI 62.5%–81.6%) following AL alone (p = 0.127).
Compared to CQ or AL alone, the risk of recurrence was significantly lower when treatment
was combined with PQ: 20.5% (95% CI 13.0%–31.5%) following CQ+PQ (HR = 5.4 [95% CI
3.0–9.7] compared to CQ alone, p< 0.001) and 22.0% (95% CI 14.2%–33.1%) following AL
+PQ (HR = 5.2 [95% CI 3.0–9.0] compared to AL alone, p< 0.001). There was no difference
in the risk of recurrence at the end of the study between patients treated with CQ+PQ and AL
+PQ (Fig 2; Tables 2 and 3).
Fig 2. Cumulative risk of P. vivax recurrence in all four treatment arms over the entire follow-up time.
AL, artemether-lumefantrine; AL+PQ, artemether-lumefantrine + primaquine; CQ, chloroquine; CQ+PQ,
chloroquine + primaquine.
https://doi.org/10.1371/journal.pmed.1002299.g002
Table 3. Hazard ratios and incidence rate ratios.
Time point Measure CQ versus CQ+PQa AL versus AL+PQa AL versus CQ AL+PQ versus CQ+PQ
Day 28 Hazard ratio —, p = 0.0001 5.1 (1.1–23.5), p = 0.034 2.9 (0.9–9.0), p = 0.07 —, p = 0.08
Day 42 Hazard ratio 18.5 (2.5–138.5), p = 0.005 5.9 (2.3–15.3), p < 0.001 1.8 (1.0–3.2), p = 0.059 5.4 (0.6–46.6), p = 0.122
End of follow-up Hazard ratio 5.4 (3.0–9.7), p < 0.001 5.2 (3.0–9.0), p < 0.001 1.3 (0.9–1.9), p = 0.127 1.3 (0.6–2.6), p = 0.523
Incidence rate ratio 5.1 (2.9–9.1), p < 0.001 6.4 (3.6–11.3), p < 0.001 0.9 (0.6–1.4), p = 0.530 1.1 (0.5–1.9), p = 0.964
Hazard ratios (95% CIs) calculated from Cox regression. Incidence rate ratios (95% CIs) calculated at the end of follow-up.
aExcluding patients not randomized to PQ versus no PQ.
AL, artemether-lumefantrine; AL+PQ, artemether-lumefantrine + primaquine; CQ, chloroquine; CQ+PQ, chloroquine + primaquine.
https://doi.org/10.1371/journal.pmed.1002299.t003
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Recurrent P. vivax infections occurred later in the PQ arms than the monotherapy arms.
The median time of the first recurrence was 82.5 d (interquartile range [IQR] 61.0–186.5) for
CQ+PQ compared to 51 d (IQR 42.0–86.0) for CQ alone (p = 0.006) and 87 d (IQR 35.0–
117.0) for AL+PQ compared to 49.5 d (IQR 35.0–98.0) for AL alone (p = 0.040). In the no-PQ
arms, 90.8% (108/119) of the recurrent parasitaemias occurred within the first 6 mo.
A total of 322 P. vivax recurrent infections were detected by microscopy during follow-up
(134 after AL, 133 after CQ, 29 after AL+PQ, and 26 after CQ+PQ) (Fig 3). The incidence rate
was 2.3 (95% CI 1.9–2.7) episodes per person-year of observation (PYO) for AL, 2.2 (95% CI
1.8–2.6) for CQ, 0.5 (95% CI 0.3–0.7) for AL+PQ, and 0.4 (95% CI 0.3–0.6) for CQ+PQ
(Table 3).
Table 4. Parasite and fever clearance by treatment arm.
Time point Chloroquine Artemether-lumefantrine Chloroquine plus primaquine Artemether-lumefantrine plus primaquine
Parasitaemia
Day 1 64.4% (67/104) 35.0% (35/100) 55.9% (57/102) 28.3% (26/92)
Day 2 4.8% (5/104) 5.0% (5/100) 8.8% (9/102) 0% (0/92)
Day 3 1.9% (2/104) 0% (0/100) 0% (0/102) 0% (0/92)
Fever
Day 1 10.5% (4/38) 0% (0/46) 2.4% (1/42) 2.6% (1/39)
Day 2 0% (0/37) 0% (0/45) 0% (0/43) 2.6% (1/39)
Day 3 0% (0/36) 0% (0/45) 0% (0/42) 2.6% (1/38)
https://doi.org/10.1371/journal.pmed.1002299.t004
Fig 3. Histogram of the distribution of the number of recurrent P. vivax infections occurring during the 1-y
follow-up period. AL, artemether-lumefantrine; AL+PQ, artemether-lumefantrine + primaquine; CQ, chloroquine;
CQ+PQ, chloroquine + primaquine.
https://doi.org/10.1371/journal.pmed.1002299.g003
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Partial primaquine dose and unsupervised primaquine treatment
The initial treatment with PQ was supervised on scheduled clinic days, and adherence assessed
by tablet review at the subsequent visit. The total PQ dose administered per unit body weight
was 3.4 mg/kg (IQR 2.8–4.0) in the AL+PQ arm and 3.5 mg/kg (IQR 2.6–4.0) in the CQ+PQ
arm. The histogram of PQ dose distribution shows distinct populations that correspond to
patients who received a total PQ dose below 2.6 mg/kg and the rest (S1 Fig). There were 27
patients in the CQ+PQ arm and 22 patients in the AL+PQ arm who received a dose below 2.6
mg/kg, and these patients appeared to be at greater risk of recurrence by 6 mo compared to
those who received a dose >2.6 mg/kg: HR = 3.8 (95% CI 1.1–13.0) for CQ+PQ and HR = 2.8
(95% CI 1.0–8.0) for AL+PQ, p = 0.036 and p = 0.059, respectively.
For all subsequent recurrences, only the first dose of the antimalarial drugs was supervised.
The risk of recurrence after 6 mo of follow-up between the primary and secondary treatments
did not differ significantly for patients in either the CQ arm (HR = 1.2 [95% CI 0.8–1.84],
p = 0.5) or the AL arm (HR = 0.8 [95% CI 0.5–1.3], p = 0.4). However, patients were at signifi-
cantly greater risk of recurrent P. vivax after the unsupervised PQ retreatment than after the
partially supervised initial PQ treatment: 86.8% (95% CI 77.3%–92.5%) versus 63.2% (95% CI
31.7%–93.3%) in patients in the CQ+PQ arm (HR = 3.9 [95% CI 1.3–11.4], p = 0.014) and
84.0% (95% CI 74.0%–90.4%) versus 51.9% (95% CI 24.4%–73.7%) in patients in the AL+PQ
arm (HR = 3.5 [95% CI 1.4–8.9], p = 0.008) (S2 Fig).
Safety
A total of 358 AEs were reported, but no serious AEs. There was no difference in the occur-
rence of any of the categories of AEs between treatment arms or by total PQ dosage received.
The most frequent AEs were headache (25.5%), fever (18.8%), chills (9.2%), cough (7.0%),
vomiting (6.7%), body pain (5.0%), abdominal pain (4.8%), weakness (4.2%) and diarrhoea
(4.0%) (Table 5).
The nadir of Hb concentration occurred on day 3 irrespective of treatment. The mean per-
centage fall from baseline by day 3 was 6.3% (95% CI 5.0%–7.7%) in the CQ arm, 5.7% (95%
CI 4.3%–7.1%) in the AL arm, 5.9% (95% CI 4.4%–7.4%) in the CQ+PQ arm, and 7.6% (95%












27 (29.7%) 29 (31.9%) 19 (20.9%) 16 (17.6%) 0.68
Fever 67
(18.8%)
13 (19.4%) 18 (26.9%) 16 (23.9%) 20 (29.9%) 0.16
Chills 33 (9.2%) 11 (33.3%) 12 (36.4%) 5 (15.2%) 5 (15.2%) 0.43
Cough 25 (7.0%) 8 (32.0%) 5 (20.0%) 8 (32.0%) 4 (16.0%) 0.53
Vomiting 24 (6.7%) 7 (29.2%) 5 (20.8%) 7 (29.2%) 5 (20.8%) 0.79
Body pain 18 (5.0%) 3 (16.7%) 6 (3.3%) 5 (27.8%) 4 (22.2%) 0.77
Abdominal pain 17 (4.8%) 7 (41.2%) 3 (17.6%) 4 (23.5%) 3 (17.6%) 0.55
Weakness 15 (4.2%) 5 (33.3%) 5 (33.3%) 4 (26.7%) 1 (6.7%) 0.59
Diarrhoea 15 (4.0%) 4 (26.7%) 3 (20.0%) 4 (26.7%) 4 (26.7%) 0.86
Fever and headache 13 (3.6%) 1 (7.7%) 5 (38.5%) 2 (15.4%) 5 (38.5%) 0.20
Nausea 12 (3.4%) 4 (33.3%) 5 (41.7%) 1 (8.3%) 2 (16.7%) 0.54
Data are given as n (percent).
https://doi.org/10.1371/journal.pmed.1002299.t005
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CI 5.1%–10.0%) in the AL+PQ arm (p = 0.577). On day 3, 3.6% (7/195) of patients treated with
a PQ regimen had anaemia (Hb< 100 g/l) compared to 4.2% (8/191) of those treated with a
no-PQ regimen (p = 0.08). By day 28, haematological recovery occurred in 211 (70.8%)
patients. Hb concentration did not fall below 80 g/l in any of the patients during the study
period, and no patient required blood transfusion.
Discussion
This study highlights that the combination of PQ with either CQ or AL reduced the risk of
early recurrence (within 42 d) of P. vivax by up to 3-fold, and decreased the risk of recurrence
over 1 y by 2- to 3-fold, compared to CQ or AL alone. PQ (3.5 mg/kg over 14 d) was well toler-
ated, without significant adverse effects. Recent clinical trials have highlighted the declining
efficacy of CQ against P. vivax in Ethiopia [18–20], with the risk of recurrence at day 28 rang-
ing from 14% [21] to 22% [20]. Our study provides evidence of low-grade CQ resistance
[4,22], with 3.8% of patients having recurrence by day 28 in the presence of adequate CQ
blood concentration (>100 nM). However, despite CQ’s compromised efficacy, the risk of
recurrence was almost 2-fold greater in patients treated with AL alone compared to those
treated with CQ alone, although this difference did not reach statistical significance
(p = 0.059). In equatorial regions endemic for P. vivax, including Ethiopia, the risk of P. vivax
relapse is generally high, with the first recurrence occurring about 21 d following the initial
treatment [23]. Lumefantrine has an elimination half-life of 3–6 d, and, by 16 d, drug concen-
trations have fallen well below the minimum inhibitory concentration for the parasite and
thus are no longer sufficient to prevent relapsing infections. Conversely, the slower elimination
of CQ affords prolonged post-treatment prophylaxis, capable of suppressing early relapses
[24]. By day 42, both CQ and lumefantrine levels are expected to be below the minimum inhib-
itory concentration, and, hence, in the absence of PQ, it is not surprising that there was no dif-
ference in the incidence of recurrent infections beyond that time.
The prolonged duration of the study and repeated administration of the same treatment
regimen for each episode of malaria allowed quantification of the cumulative risk of P. vivax
and incidence of recurrence over a 12-mo period. The incidence of infection reflects the likely
impact that would result from corresponding policy change. Patients receiving CQ or AL
alone had four or five recurrences, with an overall incidence rate of approximately two epi-
sodes per PYO. The addition of a supervised 14-d regimen of PQ resulted in a 4-fold reduction
in the incidence rate, from 2 to 0.5 episodes per PYO. Radical cure with PQ is a function of the
total mg/kg dose administered [25,26], and this was highlighted by a clear dose response in
our study. Patients who received a total PQ dose below 2.6 mg/kg had significantly more recur-
rences than those who received a greater dose: almost 4-fold more in the CQ+PQ arm and
3-fold more in the AL+PQ arm (p< 0.05).
There was also a 3- to 4-fold greater risk of recurrence following treatment of patients’ first
recurrent parasitaemia (which was unsupervised) compared to that following treatment of
their initial parasitaemia (which was semi-supervised). Although this non-randomized com-
parison is vulnerable to bias, there was no difference in the risk of recurrence following the
first and second treatments with CQ or AL monotherapy, suggesting that the difference was
likely due to poor adherence to an unsupervised 14-d regimen of PQ. These findings are con-
sistent with previous studies that have shown PQ adherence falling to less than 30% when
unsupervised [27–29]. Significantly lower rates of recurrent parasitaemia were seen in a Thai
study when PQ administration was directly observed compared to when it was unsupervised
[30], although a difference was not observed in a study in Pakistan [31]. Our study emphasises
the need for improved delivery of radical cure, using DOT, shorter treatment courses, and
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greater emphasis on patient and community education to promote the importance of radical
cure and the need to continue treatment after resolution of symptoms [32].
There is reluctance of some healthcare providers to prescribe PQ, mainly due to concerns
over its safety and potential for causing severe haemolysis [33]. To ensure safe delivery of PQ,
WHO recommends prior testing for G6PD deficiency [34]. However, not many P. vivax
endemic countries have implemented this yet. Further work to understand the barriers to rou-
tine G6PD testing is currently underway. In our study, PQ was administered to individuals
confirmed to be G6PD normal at a total dose of 3.5 mg/kg (a low-dose radical cure regimen)
[26]. This regimen was well tolerated, with no significant difference in the number or type of
AEs between the PQ and no-PQ study arms. The predominant decline in Hb concentration
occurred between enrolment and day 3, although PQ treatment only commenced on day 2.
Hb recovery began after day 3; the greatest fall in Hb was thus a consequence of malaria rather
than being drug-induced. Furthermore, treatment with PQ resulted in a significant reduction
in P. vivax recurrences, each of which were associated with repeated bouts of haemolysis and a
cumulative risk of anaemia [5,35].
There were a number of limitations of the study. First, the omission of routine Hb measure-
ments after day 42, except in patients with recurrent malaria, prevented quantification of the
long-term effects of recurrent episodes of malaria on the cumulative risk of anaemia. Further
studies are needed to define the risk and benefits of alternative PQ dosing strategies in differ-
ent endemic settings. Second, whilst all of the early recurrent parasitaemias were genotyped
and compared with the pre-treatment parasitaemia, this comparison was not undertaken for
recurrent infections after day 42. Heterologous recurrences occurring within the first 42 d can
be due to either reinfection or relapse events but not true recrudescences. Parasite genotyping
allows these events to be censored, enabling a better estimate of early efficacy. However, geno-
typing of late recurrences cannot distinguish between relapsing infections, which can be either
homologous or heterologous, and reinfections. For this reason, we used a conservative
approach to quantify and compare the cumulative risk and incidence of all recurrent P. vivax
infections irrespective of whether they were homologous or heterologous. Third, the early ter-
mination of our trial reduced the final sample size. However, loss to follow-up was lower than
assumed in the prior power calculation, and the final sample size enrolled into the study still
achieved a power of greater than 80% for the primary outcomes of the study.
In conclusion, although there was evidence of low-grade CQ resistance of P. vivax in our
study, the risk of early recurrence appeared greater following AL, likely due to relapsing infec-
tions emerging after the post-treatment prophylaxis of AL had waned. When administered as
monotherapy, there was little benefit of changing the first-line therapy for vivax malaria from
CQ to AL in this region of Ethiopia. However, PQ treatment should be included in future revi-
sion of the national treatment guidelines to decrease relapse rates, with likely benefits in reduc-
ing both malarial anaemia and transmission potential. Better methods of ensuring adequate
adherence will be needed if the public health impact is to be maximised.
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